Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:56PM ET
1.81
Dollar change
-0.01
Percentage change
-0.55
%
Index- P/E- EPS (ttm)-0.86 Insider Own27.55% Shs Outstand32.17M Perf Week-4.23%
Market Cap58.23M Forward P/E- EPS next Y-1.28 Insider Trans0.06% Shs Float23.30M Perf Month-11.27%
Income-25.79M PEG- EPS next Q-0.24 Inst Own20.69% Short Float0.98% Perf Quarter-4.23%
Sales0.00M P/S- EPS this Y-17.83% Inst Trans-0.79% Short Ratio1.08 Perf Half Y35.07%
Book/sh0.76 P/B2.38 EPS next Y-26.64% ROA-60.26% Short Interest0.23M Perf Year-11.27%
Cash/sh0.93 P/C1.95 EPS next 5Y- ROE-79.69% 52W Range0.90 - 3.49 Perf YTD-2.16%
Dividend Est.- P/FCF- EPS past 5Y-21.09% ROI-105.37% 52W High-48.14% Beta1.62
Dividend TTM- Quick Ratio3.37 Sales past 5Y0.00% Gross Margin- 52W Low101.09% ATR (14)0.13
Dividend Ex-Date- Current Ratio3.37 EPS Y/Y TTM3.78% Oper. Margin0.00% RSI (14)41.37 Volatility5.88% 7.25%
Employees28 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-48.01% Payout- Rel Volume0.87 Prev Close1.82
Sales Surprise- EPS Surprise15.62% Sales Q/Q- EarningsMar 26 BMO Avg Volume210.69K Price1.81
SMA20-5.06% SMA50-13.21% SMA2005.28% Trades Volume156,023 Change-0.55%
Date Action Analyst Rating Change Price Target Change
Nov-03-21Initiated Oppenheimer Outperform $22
Nov-03-21Initiated B. Riley Securities Buy $27
Mar-27-24 09:31AM
01:13AM
Mar-26-24 11:53AM
07:00AM
Mar-15-24 07:30AM
04:05PM Loading…
Mar-14-24 04:05PM
Mar-11-24 08:16PM
04:05PM
Mar-06-24 07:30AM
Feb-26-24 07:30AM
Feb-06-24 08:47AM
Jan-04-24 07:30AM
Nov-16-23 07:30AM
Nov-15-23 07:30AM
Nov-07-23 07:30AM
06:00AM Loading…
Nov-03-23 06:00AM
Nov-02-23 07:30AM
Oct-27-23 07:30AM
Oct-24-23 04:30PM
Oct-16-23 07:30AM
Sep-07-23 07:45AM
Aug-30-23 08:00AM
Aug-09-23 09:09AM
Aug-08-23 09:52PM
07:00AM
Aug-02-23 07:30AM
Jul-11-23 07:30AM
Jul-05-23 07:30AM
Jun-28-23 07:00AM
Jun-27-23 07:17PM
07:30AM Loading…
Jun-20-23 07:30AM
Jun-02-23 07:30AM
May-23-23 09:40AM
07:30AM
May-18-23 03:53PM
07:30AM
May-04-23 04:05PM
May-01-23 07:30AM
Apr-19-23 07:30AM
Apr-12-23 07:30AM
Mar-28-23 07:30AM
Mar-27-23 08:00AM
07:12AM
Mar-23-23 11:03PM
07:30AM
Mar-21-23 08:00AM
Mar-16-23 12:18PM
07:30AM
Mar-15-23 07:30AM
Mar-07-23 08:00AM
Feb-22-23 08:00AM
Feb-21-23 07:30AM
Feb-20-23 08:50AM
Feb-09-23 08:00AM
Dec-22-22 08:00AM
Dec-21-22 04:05PM
Dec-15-22 08:00AM
Dec-01-22 08:38AM
07:30AM
Nov-28-22 08:00AM
Nov-21-22 08:00AM
Nov-15-22 12:55PM
Nov-14-22 08:00AM
Nov-10-22 08:00AM
Oct-12-22 08:00AM
Oct-11-22 08:00AM
Sep-29-22 07:30AM
Sep-27-22 07:32AM
Sep-06-22 07:32AM
Aug-11-22 06:56AM
Aug-09-22 07:00AM
Aug-04-22 04:02PM
02:30PM
Aug-03-22 04:05PM
Jul-19-22 08:00AM
Jun-23-22 07:30AM
Jun-08-22 07:30AM
Jun-02-22 04:01PM
May-13-22 07:30AM
May-11-22 07:00AM
May-04-22 05:54PM
04:01PM
May-03-22 08:00AM
May-02-22 11:18AM
Apr-25-22 04:01PM
08:00AM
Apr-06-22 07:30AM
Mar-30-22 07:00AM
Mar-22-22 08:00AM
Mar-10-22 07:30AM
Mar-08-22 08:00AM
Feb-08-22 07:30AM
Jan-10-22 07:30AM
Jan-08-22 07:01AM
Jan-04-22 07:30AM
Dec-21-21 07:30AM
Nov-30-21 07:30AM
Nov-18-21 08:00AM
Nov-15-21 07:30AM
Nov-03-21 08:00AM
Cognition Therapeutics, Inc. is a clinical stage neuroscience company, which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy, and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ricciardi LisaCEO & PresidentMar 14 '24Buy1.755,7009,975291,345Mar 14 04:34 PM
Last Close
Mar 28 02:58PM ET
8.62
Dollar change
-1.15
Percentage change
-11.81
%
LTRN Lantern Pharma Inc daily Stock Chart
Index- P/E- EPS (ttm)-1.47 Insider Own26.51% Shs Outstand10.72M Perf Week-4.49%
Market Cap92.63M Forward P/E- EPS next Y-1.92 Insider Trans-19.65% Shs Float7.89M Perf Month69.12%
Income-15.96M PEG- EPS next Q-0.43 Inst Own10.93% Short Float1.83% Perf Quarter116.17%
Sales0.00M P/S- EPS this Y-35.15% Inst Trans0.92% Short Ratio0.56 Perf Half Y129.39%
Book/sh3.82 P/B2.26 EPS next Y3.61% ROA-31.15% Short Interest0.14M Perf Year89.14%
Cash/sh3.85 P/C2.24 EPS next 5Y- ROE-32.93% 52W Range2.38 - 11.99 Perf YTD101.52%
Dividend Est.- P/FCF- EPS past 5Y-39.81% ROI-38.96% 52W High-28.07% Beta1.42
Dividend TTM- Quick Ratio16.18 Sales past 5Y0.00% Gross Margin- 52W Low262.39% ATR (14)1.25
Dividend Ex-Date- Current Ratio16.18 EPS Y/Y TTM-12.02% Oper. Margin0.00% RSI (14)55.68 Volatility15.24% 18.88%
Employees21 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price20.50
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-24.47% Payout- Rel Volume1.10 Prev Close9.78
Sales Surprise- EPS Surprise2.50% Sales Q/Q- EarningsMar 18 AMC Avg Volume256.49K Price8.62
SMA2013.98% SMA5056.42% SMA20090.88% Trades Volume238,497 Change-11.81%
Date Action Analyst Rating Change Price Target Change
Oct-07-21Initiated H.C. Wainwright Buy $32
Mar-20-24 09:00AM
Mar-19-24 09:06AM
Mar-18-24 08:53PM
05:32PM
04:02PM
08:00AM Loading…
Mar-15-24 08:00AM
Mar-11-24 07:30AM
Mar-07-24 06:17AM
Mar-05-24 08:01AM
Mar-04-24 08:01AM
Feb-20-24 08:01AM
Feb-15-24 08:01AM
Jan-17-24 07:30AM
Dec-13-23 08:05AM
Nov-30-23 08:00AM
11:31AM Loading…
Nov-10-23 11:31AM
Nov-08-23 06:43PM
04:01PM
Nov-01-23 08:00AM
Oct-24-23 04:03PM
Oct-10-23 08:00AM
Oct-03-23 08:00AM
Sep-29-23 07:40AM
Sep-25-23 08:30AM
Sep-18-23 09:00AM
Sep-14-23 09:09AM
Aug-31-23 08:00AM
Aug-28-23 05:32PM
08:00AM
Aug-23-23 06:00PM
08:30AM Loading…
Aug-14-23 08:30AM
Aug-10-23 08:37AM
Aug-09-23 04:01PM
09:11AM
Aug-08-23 03:06PM
Aug-02-23 12:45PM
08:00AM
Aug-01-23 07:30PM
Jul-30-23 02:45PM
Jul-17-23 08:00AM
Jun-26-23 08:30AM
Jun-12-23 08:30AM
Jun-08-23 09:00AM
May-19-23 06:50AM
May-17-23 08:00AM
May-10-23 09:59AM
May-09-23 04:01PM
May-03-23 09:00AM
May-02-23 04:01PM
07:30AM
Apr-13-23 07:30AM
Mar-28-23 08:00AM
Mar-24-23 07:15AM
Mar-22-23 11:50AM
11:45AM
Mar-21-23 04:01PM
12:11PM
Mar-20-23 04:01PM
Mar-15-23 08:00AM
Mar-13-23 08:00AM
06:16AM
06:00AM
Mar-09-23 08:00AM
Mar-08-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-27-23 08:00AM
Feb-21-23 12:10PM
Feb-15-23 08:00AM
Feb-01-23 04:55AM
Jan-17-23 08:00AM
Jan-05-23 08:59AM
Dec-31-22 06:15AM
Dec-15-22 08:00AM
Dec-13-22 08:00AM
Dec-02-22 01:46PM
08:00AM
Nov-22-22 08:00AM
Nov-08-22 04:48AM
Nov-07-22 04:01PM
Nov-02-22 08:00AM
Oct-31-22 08:00AM
Oct-25-22 08:00AM
Oct-21-22 07:00AM
Oct-20-22 07:59AM
Oct-13-22 10:48AM
Oct-11-22 04:00PM
Oct-05-22 08:00AM
Sep-23-22 08:50AM
Sep-19-22 08:50AM
Sep-14-22 12:05PM
08:50AM
Aug-30-22 09:00AM
Aug-19-22 08:30AM
Aug-09-22 08:20AM
Aug-08-22 04:01PM
Aug-01-22 07:00AM
Jul-14-22 07:00AM
May-12-22 07:00AM
May-06-22 10:29AM
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kreis Leslie W.10% OwnerFeb 29 '24Sale4.8719,70395,95460,256Feb 29 09:54 PM
Fletcher Aaron G.L.10% OwnerFeb 29 '24Sale4.8719,70395,95460,256Feb 29 09:54 PM
Fletcher Aaron G.L.10% OwnerFeb 28 '24Sale4.8574,297360,34062,088Feb 29 09:54 PM
Kreis Leslie W.10% OwnerFeb 28 '24Sale4.8574,297360,34062,088Feb 29 09:54 PM
Kreis Leslie W.10% OwnerFeb 27 '24Sale4.4050,000220,00068,997Feb 29 09:54 PM
Fletcher Aaron G.L.10% OwnerFeb 27 '24Sale4.4050,000220,00068,997Feb 29 09:54 PM
Kreis Leslie W.10% OwnerJan 17 '24Sale4.2058,889247,33473,646Jan 19 04:30 PM
Fletcher Aaron G.L.10% OwnerJan 17 '24Sale4.2058,889247,33473,646Jan 19 04:31 PM
Kreis Leslie W.10% OwnerNov 29 '23Sale3.44145,348499,997217,553Dec 01 06:00 AM
Fletcher Aaron G.L.10% OwnerNov 29 '23Sale3.44145,348499,997217,553Dec 01 06:01 AM
Last Close
Mar 28 02:58PM ET
1.20
Dollar change
-0.01
Percentage change
-0.83
%
INAB IN8bio Inc daily Stock Chart
Index- P/E- EPS (ttm)-1.01 Insider Own32.38% Shs Outstand43.29M Perf Week-4.00%
Market Cap51.95M Forward P/E- EPS next Y-0.55 Insider Trans0.00% Shs Float29.27M Perf Month4.35%
Income-30.01M PEG- EPS next Q-0.17 Inst Own27.27% Short Float0.29% Perf Quarter-15.49%
Sales0.00M P/S- EPS this Y35.50% Inst Trans-22.50% Short Ratio0.49 Perf Half Y11.11%
Book/sh0.58 P/B2.08 EPS next Y14.73% ROA-89.91% Short Interest0.08M Perf Year-2.44%
Cash/sh0.49 P/C2.44 EPS next 5Y- ROE-125.90% 52W Range0.65 - 3.95 Perf YTD-13.04%
Dividend Est.- P/FCF- EPS past 5Y-50.62% ROI-105.97% 52W High-69.62% Beta-0.00
Dividend TTM- Quick Ratio4.57 Sales past 5Y0.00% Gross Margin- 52W Low84.62% ATR (14)0.11
Dividend Ex-Date- Current Ratio4.57 EPS Y/Y TTM25.79% Oper. Margin0.00% RSI (14)49.24 Volatility8.46% 9.36%
Employees31 Debt/Eq0.20 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price8.62
Option/ShortNo / Yes LT Debt/Eq0.14 EPS Q/Q33.21% Payout- Rel Volume0.58 Prev Close1.21
Sales Surprise- EPS Surprise-43.51% Sales Q/Q- EarningsMar 14 AMC Avg Volume174.60K Price1.20
SMA20-1.11% SMA50-1.34% SMA200-3.35% Trades Volume85,474 Change-0.83%
Date Action Analyst Rating Change Price Target Change
Mar-18-24Initiated Laidlaw Buy $7.50
Aug-30-22Initiated H.C. Wainwright Buy $14
Mar-14-24 09:54PM
04:00PM
Mar-05-24 04:30PM
Feb-26-24 08:00AM
Feb-14-24 08:00AM
08:00AM Loading…
Jan-04-24 08:00AM
Dec-11-23 04:05PM
09:00AM
Dec-07-23 08:00AM
Dec-05-23 08:00AM
Nov-20-23 07:00AM
Nov-10-23 07:00AM
Nov-09-23 04:00PM
Nov-06-23 08:00AM
Nov-03-23 12:00PM
09:17AM Loading…
Nov-02-23 09:17AM
Nov-01-23 08:00AM
Oct-12-23 08:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-20-23 08:00AM
Sep-19-23 08:03AM
Sep-06-23 08:00AM
Aug-15-23 08:00AM
Aug-10-23 04:15PM
Aug-08-23 08:00AM
Jun-05-23 08:00AM
May-17-23 08:00AM
May-12-23 08:00AM
May-02-23 05:08PM
08:00AM Loading…
May-01-23 08:00AM
Apr-26-23 10:00AM
Apr-25-23 08:00AM
Apr-24-23 08:00AM
Apr-17-23 09:00AM
Apr-11-23 08:00AM
Mar-30-23 04:15PM
Mar-16-23 08:00AM
Mar-01-23 08:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Jan-17-23 07:00AM
Jan-05-23 07:00AM
Jan-03-23 07:00AM
Dec-12-22 07:00AM
Dec-08-22 07:00AM
Nov-10-22 07:30AM
Nov-03-22 09:10AM
Nov-01-22 07:30AM
Sep-27-22 07:30AM
Sep-15-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 07:30AM
Aug-30-22 04:15PM
Aug-19-22 09:20AM
Aug-16-22 04:15PM
Aug-12-22 04:15PM
Aug-11-22 10:05PM
Jul-27-22 07:00AM
Jul-21-22 07:00AM
Jul-12-22 08:00AM
Jul-10-22 09:12AM
Jun-30-22 04:15PM
Jun-08-22 08:00AM
Jun-06-22 07:00AM
May-17-22 07:00AM
May-12-22 08:00AM
May-05-22 08:00AM
May-04-22 08:00AM
May-03-22 11:00AM
Apr-13-22 08:30AM
Apr-05-22 04:15PM
Mar-28-22 08:00AM
Mar-17-22 04:15PM
Mar-04-22 07:00AM
Feb-10-22 05:36PM
Jan-31-22 12:29PM
Jan-10-22 07:00AM
Jan-06-22 07:00AM
Dec-16-21 07:00AM
Dec-09-21 04:30PM
Nov-16-21 07:00AM
Nov-11-21 07:00AM
Nov-10-21 04:15PM
Nov-04-21 08:00AM
Nov-01-21 09:28AM
Oct-27-21 07:00AM
Oct-04-21 04:15PM
Sep-10-21 04:15PM
Aug-30-21 07:00AM
Aug-11-21 08:00AM
Aug-04-21 08:00AM
Jul-30-21 07:00AM
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Graff Jeremy R.DirectorSep 13 '23Buy0.952,5002,3752,500Sep 15 04:51 PM
McCall PatrickChief Financial OfficerAug 25 '23Buy1.031,0001,0306,263Aug 28 04:43 PM
Ho William Tai-WeiPresident and CEOAug 24 '23Buy1.0523,80024,9902,339,545Aug 28 04:42 PM